GlassScriptPhysician profile
Cassandra C Kessler
NPI 1447760251
$2,839.06
in general payments reported to CMS, 2019-2025
22 companies · $839 in 2025
The $839 reported for 2025 was more than what 96% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $28.57 · 2023: $367 · 2024: $1,300 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $683.75 | 2023-2025 | Provenge |
| Sumitomo Pharma America, INC. | $527.43 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $242.94 | 2024-2025 | |
| Janssen Biotech, INC. | $216.23 | 2023-2025 | Erleada, Akeega, Balversa |
| Janssen Scientific Affairs, LLC | $185.98 | 2024 | Akeega, Erleada |
| Astellas Pharma US INC | $166.34 | 2021 | |
| Olympus America INC. | $163.89 | 2023 | Itind System |
| Endo USA, INC. | $144.34 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $116.89 | 2024 | Adstiladrin |
| Urogen Pharma, INC. | $87.02 | 2022-2025 | Jelmyto |
| Accord Healthcare, INC. | $44.70 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $36.25 | 2022-2023 | Xiaflex, Aveed |
| Tolmar Pharmaceuticals, INC. | $30.03 | 2021 | |
| Coloplast Corp | $28.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.45 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.31 | 2023 | |
| Amgen INC. | $23.74 | 2021 | |
| 180 Medical, INC. | $23.07 | 2021 | |
| Myriad Genetic Laboratories, INC. | $17.51 | 2024 | Myrisk |
| Clarus Therapeutics INC. | $17.37 | 2021 | |
| Verity Pharmaceuticals INC. | $16.08 | 2025 | Tlando |
| Astrazeneca Pharmaceuticals LP | $14.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.